Morphic Therapeutic

Morphic Therapeutic

  • Founded: 2016
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Ulcerative colitis, Crohn's
  • Drug types: GI, ONC, CVV
  • Lead product: MORF-057
  • Product link: https://morphictx.com/pipeline/
  • Funding: $240M stock May 2023; $245M stock Mar 2021; $90M IPO Jun 2019; $80M B Sep 2018; $51.5M A Jul 2016


morphictx.com

linkedin.com

job board


Short description:

Oral Integrin Drugs

Drug notes:

4 undisclosed programs RD/Clin0 GI conditions, solid tumors, fibrotic conditions, PAH, undisclosed

Long description:

Morphic Therapeutic is developing a new generation of oral integrin therapies to treat autoimmune, cardiovascular and metabolic diseases. Integrins are receptors found at the cell membrane and are involved in many cellular processes by signaling bi-directionally. Malfunctions in the integrins are linked with disease. Using their proprietary MInT drug discovery platform and knowledge from integrin research leaders, Morphic is in the position to target all 24 known human integrins to stabilize their conformation or to activate or inhibit their activity to modify disease. One molecule (MORF-057) is already in Phase I clinical trials for inflammatory bowel disease.

Jobs:

Morphic Therapeutic
Director, GMP Quality Management
Waltham, MA|Not provided
Apply
Morphic Therapeutic
Associate Director/Director, Trial Master File Man...
Waltham, MA|Not provided
Morphic Therapeutic
Executive Director, Medical Affairs
Waltham, MA|Not provided
Morphic Therapeutic
Executive Director, Drug Safety and Pharmacovigila...
Waltham, MA|Not provided
Morphic Therapeutic
Senior Director, Clinical Outsourcing Management
Waltham, MA|Not provided
Morphic Therapeutic
Associate Director/Director of Statistical Program...
Waltham, MA|Not provided


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com